Serum Erythropoietin, Insulin-like Growth Factor 1, and Vascular Endothelial Growth Factor in Etiopathogenesis of Retinopathy of Prematurity

Yenice, Özlem; Çerman, Eren; Ashour, Ahmet; Firat, Ridvan; Haklar, Goncagül; Sirikci, Onder; Akman, İpek; Kazokoğlu, Haluk

doi:10.3928/23258160-20131105-05

Cited by 23 publications

(29 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[39][40][41] Cerebral and intestinal morbidity were negligible in all groups, and, given the relationship of VEGF to the underlying pathogenesis of retinopathy of prematurity, 42,43 it is particularly reassuring that no infant developed this condition. We acknowledge that the small sample size in this study may have precluded observation of uncommon adverse events.…”

Section: Discussionmentioning

confidence: 90%

Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia

Thadhani¹,

Hagmann²,

Schaarschmidt³

et al. 2016

Journal of the American Society of Nephrology

224

145

View full text Add to dashboard Cite

Preeclampsia is a devastating complication of pregnancy. Soluble Fms-like tyrosine kinase-1 (sFlt-1) is an antiangiogenic protein believed to mediate the signs and symptoms of preeclampsia. We conducted an open pilot study to evaluate the safety and potential efficacy of therapeutic apheresis with a plasmaspecific dextran sulfate column to remove circulating sFlt-1 in 11 pregnant women (20-38 years of age) with very preterm preeclampsia (23-32 weeks of gestation, systolic BP $140 mmHg or diastolic BP $90 mmHg, new onset protein/creatinine ratio .0.30 g/g, and sFlt-1/placental growth factor ratio .85). We evaluated the extent of sFlt-1 removal, proteinuria reduction, pregnancy continuation, and neonatal and fetal safety of apheresis after one (n=6), two (n=4), or three (n=1) apheresis treatments. Mean sFlt-1 levels were reduced by 18% (range 7%-28%) with concomitant reductions of 44% in protein/creatinine ratios. Pregnancy continued for 8 days (range 2-11) and 15 days (range 11-21) in women treated once and multiple times, respectively, compared with 3 days (range 0-14) in untreated contemporaneous preeclampsia controls (n=22). Transient maternal BP reduction during apheresis was managed by withholding pre-apheresis antihypertensive therapy, saline prehydration, and reducing blood flow through the apheresis column. Compared with infants born prematurely to untreated women with and without preeclampsia (n=22 per group), no adverse effects of apheresis were observed. In conclusion, therapeutic apheresis reduced circulating sFlt-1 and proteinuria in women with very preterm preeclampsia and appeared to prolong pregnancy without major adverse maternal or fetal consequences. A controlled trial is warranted to confirm these findings.

show abstract

Section: Discussionmentioning

confidence: 90%

Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia

Thadhani¹,

Hagmann²,

Schaarschmidt³

et al. 2016

Journal of the American Society of Nephrology

224

145

View full text Add to dashboard Cite

show abstract

“…(Peking Epidemiological Survey of Retinopathy of prematurity 2008) Any method predicting patients who would develop severe ROP would be of great value. (Yenice et al 2013) Both vascular endothelial growth factor (VEGF) and apelin are key factors in the pathogenesis of ROP, but its potential value as a predictive factor in the development of ROP has not been investigated.…”

mentioning

confidence: 99%

Vascular endothelial growth factor and apelin in plasma of patients with retinopathy of prematurity

Feng

Zhou

Zhang

et al. 2016

Acta Ophthalmologica

View full text Add to dashboard Cite

“…Two studies were carried out using cord blood,7 8 five studies compared VEGF measurements from venous blood (mostly serum levels)9–13 and in the most recent study, both cord and venous VEGF measurements were used 14. In three other studies, the relationship between IVB and VEGF was investigated15–17 and in one study, tissue specimen from a deceased neonate was analysed 18.…”

Section: Resultsmentioning

confidence: 99%

“…Yenice et al 8 also used cord blood to determine the risk for a premature neonate to develop ROP. The investigators measured IGF-1, VEGF and erythropoietin defined in a cohort of 92 premature infants (<32 weeks gestation).…”

Section: Resultsmentioning

confidence: 99%

“…In studies that measured VEGF in cord blood, low VEGF (at birth) was associated with ROP in one8 and no difference in two others 7 14. Postnatal venous VEGF measurement from four studies showed no difference in VEGF level between premature infants with and without ROP,10–12 17 one study showed increased VEGF levels in premature infants with ROP,9 another study found serum VEGF to be low in premature infants with ROP13 and the most recent study demonstrated an initial increase in serum VEGF followed by a decline at the time of treatment 14.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The association between systemic vascular endothelial growth factor and retinopathy of prematurity in premature infants: a systematic review

et al. 2016

View full text Add to dashboard Cite

Retinopathy of prematurity (ROP), a vasoproliferative disorder exclusive to premature infants is an important cause of childhood blindness. The number of premature infants surviving with this condition is expected to increase globally. Animal models of oxygen-induced retinopathy studies have shown vascular endothelial growth factor (VEGF) to be a key player in the pathogenesis of ROP. This has led to increased use of VEGF antagonist as an alternative treatment for ROP. The purpose of this systematic review is to determine the association between VEGF and ROP in human newborn. The literature review identified 12 studies to date which fulfilled the search criteria. Investigators used cord blood, serum, plasma and tissue samples to investigate the association between ROP and VEGF. Studies that measured VEGF in cord blood found mixed results, with low VEGF (at birth) associated with ROP in one study and no difference noted in two others. Mixed results were also seen in studies determining VEGF in postnatal venous samples. Four studies showed no difference in VEGF level between premature infants with and without ROP, one study showed an increased VEGF level in premature infants with ROP and another study found serum VEGF to be low in premature infants with ROP. The most recent study demonstrated an initial increase in serum VEGF followed by a decline at the time of treatment. These contradictory results indicate that we are yet to fully understand the role of VEGF in human premature infants and question the rationale of treating ROP with anti-VEGF. Anti-VEGF therapy results in systemic effect on serum VEGF levels for up to 2 months and this could have an effect on neurodevelopmental outcome. The effect of this on other developing organs is currently unknown. More studies are required to determine the mechanistic relationships between systemic VEGF and ROP in premature infants.

show abstract

Serum Erythropoietin, Insulin-like Growth Factor 1, and Vascular Endothelial Growth Factor in Etiopathogenesis of Retinopathy of Prematurity

Abstract: Serum VEGF levels at birth were lower in infants who later developed ROP. This may have a predictive value for ROP and contribute to the pathogenesis, because affected infants may be more susceptible to extrauterine hyperoxic insult.

Cited by 23 publications

References 24 publications

Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia

Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia

Vascular endothelial growth factor and apelin in plasma of patients with retinopathy of prematurity

The association between systemic vascular endothelial growth factor and retinopathy of prematurity in premature infants: a systematic review

Contact Info

Product

Resources

About